15 results about "Phosphatidyl Cholines" patented technology

This invention discloses a food-grade nanoliposome and its preparation method. Phosphatidylcholine is dissolved in anhydrous ethanol to obtain an organic phase. Ultrapure water or the water-soluble substance 5(6)-carboxyfluorescein is used as the aqueous phase. The organic and aqueous phases are mixed using a microfluidic method or an ethanol injection method to form a uniform lipid film, resulting in nanoliposomes applicable to the food industry. The aqueous phase is encapsulated within the hydrophilic region of the liposome. Since the liposomes prepared by this invention do not contain cholesterol or other substances besides phosphatidylcholine and have a good encapsulation rate, replacing the aqueous phase with nutrients allows for long-term consumption as food without causing excessive cholesterol levels in the human body. Furthermore, the encapsulation of nutrients by liposomes can improve the absorption of nutrients by the human body, demonstrating significant application potential in the food industry.

The embodiments disclosed herein relate to a liposomal composition for sustained release of an active ingredient. In various implementations, the liposomal composition may have a first liposomal core of Phosphatidylcholine (PC), phosphatidylethanolamine (PE), or phosphatidylserine (PS) and the active ingredient dispersed within the first liposomal core. A second core may surround the first liposomal core, with the second core optionally containing one or more polypeptide and a polysaccharide.

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having PI-specific phospholipase C activity as well as polypeptides having PC, PE-specific phospholipase C activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

A system for the manufacture of pharmaceutical formulations for the treatment of diabetes and diabetic neuropathy, comprising: a) an extraction unit for producing an ethanolic extract from shade-dried leaves of Moringa oleifera Lam. and Bacopa monnieri Linn., and defatting the dried, crushed leaves with petroleum ether to remove lipids and chlorophyll; b) a fractionation unit configured to fractionate the ethanolic extract with ethyl acetate to obtain the ethyl acetate fraction; c) a phytosome preparation unit for the production of phytosomes using antisolvens precipitation technology, wherein the phytosome preparation unit comprises the following: • an ultrasonic device for sonicating a mixture of ethyl acetate fraction and phosphatidylcholine, • a heating device configured to heat the sonicated mixture below 40 °C, and • a condensation device configured to condense solvents into a complex film; and d) a formulation unit configured to incorporate the phytosomes into pharmaceutical dosage forms.

The application discloses a preparation method of cherimoya leaf extract and belongs to the technical field of natural medicine extraction and preparation. The conventional preparation method of the cherimoya leaf extract in the prior art has limited bioavailability of the extract, and lacks a systematic method for effectively enriching specific active components of the extract and stably encapsulating the specific active components in a suitable delivery system. The preparation method provided by the application comprises the following steps: crushing dried cherimoya leaves, refluxing and extracting the dried cherimoya leaves with an ethanol aqueous solution, and concentrating the extract; adding ethyl acetate to the concentrated solution to perform extraction; mixing the obtained ethyl acetate extraction phase with a phospholipid aqueous dispersion liquid composed of phosphatidylcholine and phosphatidylethanolamine in a specific ratio; performing high-pressure homogenization treatment to obtain a nanoliposome suspension liquid; and finally performing spray drying to obtain an extract powder. The extract prepared by the method can be used for preparing a medicine for treating type 2 diabetes.

The application belongs to the technical field of biological medicine, and particularly relates to application of phosphatidylcholine in preparation of a medicine for preventing and treating porcine rotavirus infection. The application finds that phosphatidylcholine (PC) has significant antiviral activity in preventing and treating PoRVA infection. Experimental results show that PC can effectively inhibit PoRVA proliferation, reduce viral load, and then relieve diarrhea symptoms caused by PoRVA infection and reduce mortality. In addition, PC can also inhibit necrotic apoptosis induced by PoRVA infection, promote repair and maintenance of intestinal barrier integrity, reduce intestinal tissue damage, and reduce the risk of secondary infection. The above results show that PC has good therapeutic potential for PoRVA infection. At the same time, PC is safe in source, has good biocompatibility, and no obvious toxic side effects are observed within a reasonable dose range, and is suitable for prevention and / or treatment of PoRVA infection, and has good application prospect and popularization value.

This invention, through lipidomics and clinical sample validation, found that prospective follow-up of pre-pregnancy serum samples from women with a history of recurrent pregnancy loss (RPL) revealed that the pre-pregnancy serum levels of phosphatidylinositol PI (18:1 / 18:1) (i.e., PI 36:2), phosphatidylcholine (29:0-6:0) (i.e., PC 35:0), phosphatidylethanolamine (18:1p-18:2) (i.e., PE 36:3p), triglycerides (28:1-10:4-11:2) (i.e., TG 49:7), triglycerides (14:0-18:2-20:5) (i.e., TG 52:7), and wax esters (22:1) (i.e., WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. This confirms that the pre-pregnancy serum levels of these six lipids (PI 36:2, PC 35:0, PE 36:3p, TG 49:7, TG 52:7, WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. Decreased levels of 22:1 lipids were significantly associated with the risk of miscarriage in subsequent pregnancies. The area under the curve (AUC) of the predictive model constructed by combining six lipids reached 0.85, demonstrating good predictive efficacy. Based on these findings, this lipid combination can serve as a reliable predictor of miscarriage risk in subsequent pregnancies in RPL patients and can be used to develop diagnostic reagents or kits for preconception risk screening.

A composition to improve learning and cognitive functions, comprising a combination to promote cognitive brain performance: DHA from fish oil, phosphatidylserine and phosphatidylcholine; as well as a combination to provide energy and reduce brain fatigue: B vitamins and galangal extract.

A proliposomal delivery system and method for preparing the same is provided. The proliposomal delivery system involves a proliposomal formulation incorporating liposomal entrapment of vitamin C within a nano-emulsion that is stabilized using partially hydrolyzed guar gum. The proliposomal formulation includes ascorbic acid as the active ingredient, sunflower lecithin with a phosphatidylcholine content as an encapsulating material, and partially hydrolyzed guar gum as a dietary polysaccharide. The proliposomal formulation is a safer and more bioavailable form of vitamin C designed to minimize gastric discomfort. The proliposomal formulation offers a nutraceutical supplement aimed at managing oxidative stress, enhancing immune system function, supporting heart health, and improving skin. The process provided for preparing the proliposomal formulation is simple, cost-effective and scalable.

This invention discloses a method for recovering L-serine based on the enzymatic synthesis reaction solution of phosphatidylserine, comprising the following steps: phosphatidylcholine and L-serine undergo an enzymatic reaction under the catalysis of phospholipase, resulting in a mixed aqueous solution containing L-serine and choline; porous media and alcohol are added to the obtained mixed aqueous solution of L-serine and choline, causing crystals to precipitate, resulting in a solid mixture of L-serine and porous media; the solid mixture of L-serine and porous media is obtained through solid-liquid separation; the obtained solid mixture of L-serine and porous media is dissolved in water, and after solid-liquid separation, an L-serine solution is obtained. This invention adds porous media before crystallization, causing capillary phase separation in the L-serine aqueous solution. This capillary phase separation results in a lower saturation concentration required for L-serine crystallization and a smaller amount of ethanol consumed, thus reducing the production cost of phosphatidylserine.

Provided are three-layer seamless soft capsules, including a core, an intermediate protective layer wrapping the core, and a film layer wrapping the intermediate protective layer, wherein the intermediate protective layer contains 279-294 parts by weight of a first oily substance and 6-21 parts by weight of phospholipids; the phospholipids contain 10-60 wt% of phosphatidylcholine; and the first oily substance is a hardened oil or a hardened oil composition in a solid state at room temperature and having a melting point of 40-60℃. The present application solves the problem of capsule easy to break and leak oil caused by large oil droplets in the film layer during the manufacturing process of seamless soft capsules.

This invention provides an antioxidant composition based on maquist and its application in dry eye prevention products. By weight, the composition includes: 8-18 parts of maquist anthocyanin extract, 4-9 parts of hyaluronic acid-chitosan grafted phospholipids, 12-22 parts of phosphatidylcholine, 3-6 parts of liposome stabilizer, 2-4 parts of synergistic antioxidant, 3-8 parts of osmotic pressure regulator, 0.1-0.3 parts of preservative, 2-5 parts of sodium hyaluronate, 1-3 parts of taurine, 0.5-1.5 parts of vitamin B6, 0.3-0.8 parts of lutein, and 30-60 parts of solvent. This invention provides an antioxidant composition and dry eye prevention products with good stability, safety, and practicality.

The application belongs to the technical field of organic synthesis, and particularly relates to a kind of polymeric organic base and its application in catalytic preparation of phosphatidylcholine compounds.The polymeric organic base described in the application is a two-block polymer formed by the polymerization of a bis-imidazole guanidine organic tertiary phosphine segment and a functionalized phosphocholine segment;The bis-imidazole guanidine organic tertiary phosphine segment has strong alkalinity and can efficiently catalyze the transesterification reaction;The functionalized phosphocholine segment is similar in structure to L-alpha-glycerophosphocholine, and can promote the solubility of the organic base at the initial stage of the reaction and increase the reactivity.The polymeric organic base described in the application can be used as a solid-supported catalyst for the preparation of phosphatidylcholine compounds by the transesterification reaction of fatty acid esters and L-alpha-glycerophosphocholine.

The invention discloses KIM-1 active targeting gold nanoparticles, a preparation method, and an application thereof, which belongs to the technical field of medical materials. The gold nanoparticles are modified on the surface of the gold nanoparticles with serine as a targeting ligand, which has high affinity and specificity for the kidney injury molecule KIM1. The preparation of GS-AuNPs is first synthesized, and then it is dissolved in PBS. After pH adjustment, EDC and NHS are added, serine is added, the pH is adjusted, and the product is obtained by ultrafiltration and centrifugation. The particles can be used as a CT contrast agent to detect KIM-1 in the kidney, and can also cooperate with phosphatidylcholine-modified silver nanoparticles to quantify KIM-1 in the kidney by urine analysis to achieve early non-invasive diagnosis of acute kidney injury, with low toxicity and good biocompatibility.